Blog

  • Vtesse: First Spin-out from Rare Disease Accelerator Cydan

    Today Vtesse, a newly formed biopharma company, announced that it has raised $25 million to develop novel treatments for rare diseases. It’s a significant milestone for several reasons, first and foremost because the funds will enable Vtesse to advance clinical study of VTS-270 for the treatment of a devastating genetic rare disease called Niemann-Pick Disease Type C (NPC). Currently there is no approved treatment for this lysosomal storage disease (LSD) affecting an estimated one in…

  • Open for Business:  Company Building in the Age of Open Source

    When it comes to open source business models, the rules of engagement have changed—and it’s good news for entrepreneurs. For years the concept of an “open source business model” was largely aspirational. The reinvention of software as we know it has been fueled by communities, not corporations. Passionate, creative, and intensely averse to software monopolies, these communities are accelerants and advocates for technological innovation. Yet it’s become clear over…

  • Radiology Partners: A New Image of Healthcare

    We’re all familiar with the concept of radiology and the prevalence of medical imaging – just tune into any television medical drama and you’re sure to see a group of doctors (with exceptionally great hair) musing about a fictional diagnosis over blue images on a fluorescent screen. In real life, however, the hair is not as great, and the radiology process is not as simple. Fortunately, the past ten years have brought dramatic advancements in the field of radiology with the…

  • Do your VCs have an uncomfortably high burn rate?

    * This blog is a follow-up to Fortune’s Dan Primack and his post: "The startup world's other 'cash burn' problem” where he suggests that venture capitalists, by and large, have a burn rate problem.  Over the past several weeks, much attention has been placed on unquestionably high start-up burn rates and whether entrepreneurs should change their current operating models in the face of a potential downturn.   But an equally important question for…

  • Abbott Sets Hearts Aflutter In Partnerships with NEA Medical Device Companies

    Global Healthcare Company Building Leading Catheter-Based Electrophysiology Franchise Atrial fibrillation (AF), a type of heart rhythm disorder that affects well over 30 million people around the world, is an increasingly common disease. The  burden of AF on a growing number of  patients and its associated healthcare costs have spurred a race among large medical device companies to develop comprehensive portfolios of diagnostic and therapeutic solutions to address this large and…